Jeffrey W. Albers Sells 5,000 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) Stock

Blueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) Director Jeffrey W. Albers sold 5,000 shares of the business's stock in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $101.14, for a total transaction of $505,700.00. Following the completion of the sale, the director now owns 146,630 shares in the company, valued at approximately $14,830,158.20. This trade represents a 3.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Blueprint Medicines Trading Down 0.1%

Blueprint Medicines stock traded down $0.19 during trading hours on Tuesday, hitting $127.60. The company had a trading volume of 20,102,612 shares, compared to its average volume of 1,049,647. The firm has a market cap of $8.24 billion, a P/E ratio of -118.15 and a beta of 0.83. The company has a debt-to-equity ratio of 1.15, a quick ratio of 2.80 and a current ratio of 2.85. Blueprint Medicines Co. has a 1 year low of $73.04 and a 1 year high of $128.21. The company has a 50-day moving average price of $92.42 and a two-hundred day moving average price of $94.93.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.32). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. The business had revenue of $149.41 million during the quarter, compared to analysts' expectations of $158.31 million. During the same period in the previous year, the company posted $1.40 EPS. Blueprint Medicines's revenue for the quarter was up 55.5% on a year-over-year basis. On average, sell-side analysts anticipate that Blueprint Medicines Co. will post -1.28 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. JMP Securities restated a "market perform" rating on shares of Blueprint Medicines in a report on Tuesday. Jefferies Financial Group started coverage on shares of Blueprint Medicines in a report on Monday, March 17th. They issued a "buy" rating and a $135.00 target price on the stock. Morgan Stanley started coverage on shares of Blueprint Medicines in a report on Thursday, March 20th. They set an "equal weight" rating and a $100.00 price target on the stock. Wall Street Zen upgraded shares of Blueprint Medicines from a "sell" rating to a "hold" rating in a report on Friday, May 2nd. Finally, Wolfe Research reiterated a "peer perform" rating on shares of Blueprint Medicines in a report on Tuesday. Twelve equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $125.38.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of BPMC. R Squared Ltd acquired a new stake in Blueprint Medicines during the fourth quarter valued at $51,000. Headlands Technologies LLC acquired a new stake in Blueprint Medicines during the fourth quarter valued at $65,000. Thematics Asset Management acquired a new stake in Blueprint Medicines during the fourth quarter valued at $72,000. Covestor Ltd lifted its holdings in Blueprint Medicines by 62.7% during the fourth quarter. Covestor Ltd now owns 973 shares of the biotechnology company's stock valued at $85,000 after purchasing an additional 375 shares in the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S purchased a new position in Blueprint Medicines during the first quarter valued at $87,000.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.